Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.

Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.

Item
http://www.wikidata.org/entity/Q37144253
Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disordersCannabinoids and Viral Infections.Marijuana use in hepatitis C infection does not affect liver biopsy histology or treatment outcomes.IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy.The impact of lifetime drug use on hepatitis C treatment outcomes in insured members of an integrated health care planCannabis sativa and the endogenous cannabinoid system: therapeutic potential for appetite regulation.Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.The gastrointestinal pharmacology of cannabinoids: focus on motility.Medical marijuana for digestive disorders: high time to prescribe?Effects of cannabinoids and their receptors on viral infections.Preferences and perceived involvement in treatment decision making among Chinese patients with chronic hepatitis.A nonsynonymous polymorphism in cannabinoid CB2 receptor gene is associated with eating disorders in humans and food intake is modified in mice by its ligands.
P2860

Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.

Item
http://www.wikidata.org/entity/Q37144253
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of oral cannabinoid ...... for chronic hepatitis C virus.
@en
Evaluation of oral cannabinoid ...... for chronic hepatitis C virus.
@nl
type
label
Evaluation of oral cannabinoid ...... for chronic hepatitis C virus.
@en
Evaluation of oral cannabinoid ...... for chronic hepatitis C virus.
@nl
prefLabel
Evaluation of oral cannabinoid ...... for chronic hepatitis C virus.
@en
Evaluation of oral cannabinoid ...... for chronic hepatitis C virus.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P932
P356
P1433
P1476
Evaluation of oral cannabinoid ...... for chronic hepatitis C virus.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P932